Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2009 01:15 ET | Source: Novartis Pharma AG

Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment

Prevacid®24HR prevents acid production that causes frequent heartburn pain for a full 24 hours with one pill a day Prevacid®24HR provides America's 50 million frequent heartburn...
November 05, 2009 01:16 ET | Source: Novartis Pharma AG

Novartis erhält für Celtura®, den Influenza A(H1N1)-Pandemie-Impfstoff auf Zellkulturbasis, die Zulassung in Deutschland

Zulassung ist wichtiger Meilenstein, um die 50 Jahre alte eibasierte Impfstoffproduktion durch moderne Biotechnologie abzulösen Klinische Studien mit mehr als 1850 Probanden in allen...
November 05, 2009 01:15 ET | Source: Novartis Pharma AG

Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine

Approval marks an important milestone in the process of replacing 50 year-old egg-based flu vaccine production with modern biotechnology Clinical trials in more than 1,850 individuals across all...
November 04, 2009 01:00 ET | Source: Novartis Pharma AG

Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan

Tianyuan a privately-held vaccines company providing a competitive product portfolio and pipeline in China, where Novartis has a limited vaccines presence Tianyuan and Novartis to collaborate...
November 03, 2009 01:15 ET | Source: Novartis Pharma AG

Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China

Novartis Institute of BioMedical Research in Shanghai, an integral part of the Novartis global R&D network worldwide, to rank third largest for Novartis worldwide Additional USD 250...
October 29, 2009 02:15 ET | Source: Novartis Pharma AG

Novartis on track to deliver Influenza A (H1N1) vaccine for the US

Novartis on track to produce 90 million units of bulk antigen in line with commitment to US Department of Health and Human Services, despite very low yields of initial seed virus 90...
October 28, 2009 02:15 ET | Source: Novartis Pharma AG

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

First drug approved in EU for patients as young as four years old with cryopyrin-associated periodic syndrome (CAPS)[1] Approval based on positive data showing Ilaris produced rapid and sustained...
October 23, 2009 01:15 ET | Source: Novartis Pharma AG

Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure

Exforge HCT combines the efficacy of three widely prescribed blood pressure treatments, valsartan, amlodipine and hydrochlorothiazide, in a single pill Up to 85% of patients may need multiple...
October 22, 2009 00:59 ET | Source: Novartis Pharma AG

Novartis verzeichnet in den ersten neun Monaten 2009 eine kräftige Dynamik der neuen Produkte und erzielt eine starke operative Performance

Starkes zugrunde liegendes Wachstum des Gesundheitsportfolios in den ersten neun Monaten 2009: Getragen vom zweistelligen Zuwachs in der Division Pharmaceuticals wächst der Nettoumsatz...
October 22, 2009 00:59 ET | Source: Novartis Pharma AG

Novartis delivers strong new product momentum and operational performance in first nine months of 2009

Strong underlying growth in first nine months of 2009 from healthcare portfolio: Net sales of USD 31.3 billion rise 8% in local currencies (lc), led by double-digit expansion in...